524717
Titan Biotech share price & financials
- Price
- ₹434.1
- Market cap
- ₹1.8k Cr
- Sector
- Chemicals
What Titan Biotech does
Titan Biotech Limited is an Indian biotechnology company that manufactures microbiological culture media, culture media bases, protein hydrolysates, fermentation-derived products, plant-based extracts and other biological and nutraceutical ingredients. It earns revenue by selling these biological products to customers in India and international markets, supported by an in-house R&D base for product development. The company also exports its products, supported by a dedicated export function.
- Manufacturing plants
- 3 (Plant I, II and III, all in RIICO Industrial Area, Bhiwadi, Rajasthan)
- Core capabilities
- Fermentation, protein hydrolysates, culture media ingredients, plant-based extracts
- Dedicated export function
- Yes (DGM Export role)
Quarterly results
Q1 FY27: revenue up 28.3%, net profit up 57.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 40 | 38 | 35 | 46 | 54 +35% | 57 +50% | 49 +40% | 59 +28% |
| EBITDA | 8 | 5 | 5 | 9 | 9 +13% | 11 +120% | 10 +100% | 12 +33% |
| Net profit | 7 | 4 | 4 | 7 | 8 +14% | 9 +125% | 7 +75% | 11 +57% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −38.2% 1Y
1Y: ₹708.15 on 10 Sept 2025 → ₹437.8. High ₹1,357.8 (15 Oct 2025), low ₹220.2 (2 Mar 2026).
Financials, as filed
Revenue grew 12.7% a year over 3 years, FY23 to FY26. Operating margin narrowed to 18.9%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹144 Cr | ₹164 Cr | ₹156 Cr | ₹206 Cr |
| Operating profit | ₹30 Cr | ₹35 Cr | ₹26 Cr | ₹39 Cr |
| Operating margin | 20.5% | 21.3% | 16.7% | 18.9% |
| Interest | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| Net profit | ₹25 Cr | ₹25 Cr | ₹21 Cr | ₹31 Cr |
| Net margin | 17.3% | 15.2% | 13.5% | 15.0% |
| Cash from operations | ₹21 Cr | ₹21 Cr | ₹20 Cr | ₹30 Cr |
| Free cash flow | ₹8 Cr | ₹12 Cr | ₹12 Cr | ₹21 Cr |
| ROCE | 27.0% | 25.0% | 17.0% | 23.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr |
| Reserves | ₹60 Cr | ₹78 Cr | ₹102 Cr | ₹125 Cr | ₹158 Cr | ₹173 Cr |
| Borrowings | ₹16 Cr | ₹9 Cr | ₹9 Cr | ₹8 Cr | ₹9 Cr | ₹6 Cr |
| Other liabilities | ₹16 Cr | ₹13 Cr | ₹16 Cr | ₹15 Cr | ₹27 Cr | ₹27 Cr |
| Total liabilities | ₹101 Cr | ₹108 Cr | ₹135 Cr | ₹157 Cr | ₹202 Cr | ₹214 Cr |
| Fixed assets | ₹34 Cr | ₹35 Cr | ₹36 Cr | ₹52 Cr | ₹57 Cr | ₹62 Cr |
| Capital work in progress | ₹0 Cr | ₹4 Cr | ₹13 Cr | ₹3 Cr | ₹4 Cr | ₹2 Cr |
| Investments | ₹0 Cr | ₹4 Cr | ₹15 Cr | ₹28 Cr | ₹48 Cr | ₹60 Cr |
| Other assets | ₹67 Cr | ₹65 Cr | ₹70 Cr | ₹74 Cr | ₹95 Cr | ₹90 Cr |
| Total assets | ₹101 Cr | ₹108 Cr | ₹135 Cr | ₹157 Cr | ₹202 Cr | ₹214 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public added +0.11 pp. The shareholder count grew 14% to 18,671.
- Promoters
- 55.8%
- DIIs
- 0.0%
- Public
- 44.2%
Since Jun 2025
- Public +0.11 pp
- Promoters −0.09 pp
- DIIs −0.02 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 55.9%, Public 44.1%.Dec '23: Promoters 55.9%, Public 44.1%.Mar '24: Promoters 55.9%, DIIs 0.2%, Public 43.9%.Jun '24: Promoters 55.9%, Public 44.1%.Sep '24: Promoters 55.9%, Public 44.1%.Dec '24: Promoters 55.9%, Public 44.1%.Mar '25: Promoters 55.9%, DIIs 0.0%, Public 44.1%.Jun '25: Promoters 55.9%, DIIs 0.0%, Public 44.1%.Sep '25: Promoters 55.8%, DIIs 0.0%, Public 44.2%.Dec '25: Promoters 55.8%, DIIs 0.0%, Public 44.2%.Mar '26: Promoters 55.8%, DIIs 0.0%, Public 44.2%.Jun '26: Promoters 55.8%, DIIs 0.0%, Public 44.2%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Titan Biotech above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Titan Securities Ltd | 33.59% | unchanged |
| Investor Education And Protection Fund Authority | 9.51% | −0.07 pp |
| Tanita Leasing & Finance Limited | 9.49% | unchanged |
| Connoisseur Management Services Private Limit | 6.78% | unchanged |
| Manish Goel | 2.80% | unchanged |
| Titan Biotech Limited Unclaimed Suspense Dema | 2.36% | −0.15 pp |
| Suresh Chand Singla | 1.28% | unchanged |
| Manju Singla | 0.86% | unchanged |
| Madhu Gupta | 0.80% | unchanged |
| Raja Singla | 0.74% | unchanged |
| Supriya Singla | 0.66% | unchanged |
| Udit Singla | 0.61% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
Growth trapTo justify its price of ₹438, this stock must grow earnings at 32% every year for 7 years. Our analysis caps realistic growth at ~8%. At that growth it is worth ₹127 — downside of 71%.
- Growth the price implies
- 31.8% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 7.7% a year
- net profit, FY23–FY26
- The gap
- 0.2 pp
- -71% downside if it only repeats history
Learn to analyse Titan Biotech
Guides on how to read this kind of business and the numbers that matter.